Although cyclophilins are attractive targets for probing biology and therapeutic intervention, no subtype-selective cyclophilin inhibitors have been described. We discovered novel cyclophilin inhibitors from the in vitro selection of a DNA-templated library of 256,000 drug-like macrocycles for cyclophilin D (CypD) affinity. Iterated macrocycle engineering guided by ten X-ray co-crystal structures yielded potent and selective inhibitors (half maximal inhibitory concentration (IC50) = 10 nM) that bind the active site of CypD and also make novel interactions with non-conserved residues in the S2 pocket, an adjacent exo-site. The resulting macrocycles inhibit CypD activity with 21- to >10,000-fold selectivity over other cyclophilins and inhibit mitochondrial permeability transition pore opening in isolated mitochondria. We further exploited S2 pocket interactions to develop the first cyclophilin E (CypE)-selective inhibitor, which forms a reversible covalent bond with a CypE S2 pocket lysine, and exhibits 30- to >4,000-fold selectivity over other cyclophilins. These findings reveal a strategy to generate isoform-selective small-molecule cyclophilin modulators, advancing their suitability as targets for biological investigation and therapeutic development.
Melanoma is an aggressive cancer with rising incidence, particularly among older individuals. Despite advancements in targeted therapies for BRAF and MEK proteins and immunotherapies, many patients either fail to respond or develop resistance. For those progressing on immunotherapy, limited treatment options remain. The Cyclin D–CDK4/6–RB pathway is commonly dysregulated in melanoma, with up to 90% of cases showing alterations that activate it. Although targeting Cyclin–CDK complexes has shown promise in preclinical models, clinical responses have been suboptimal. This review explores the molecular mechanisms behind Cyclin–CDK dysregulation in melanoma and the challenges of targeting this pathway. It also discusses strategies to improve the efficacy of CDK4/6 inhibitors, including combination therapies to overcome resistance and enhance patient outcomes. Understanding these mechanisms can guide the development of more effective treatments for melanoma.
25 July 2022 in The Journal of Physical Chemistry Letters
Objective: To identify trends in industry payments (IPs) to otolaryngologists from 2017 to 2023, particularly evaluating the impact of the COVID-19 pandemic. Study Design: Cross-sectional retrospective analysis. Setting: Open Payments Database. Methods: Non-research payments to otolaryngologists 2017 to 2023 were characterized by census region, nature of payment, submitting manufacturer, and temporal trends. Results: 448,093 transactions worth $85.6 million were found with a median payment per physician of $47.81. Payments sharply decreased in 2020 during the COVID-19 pandemic ($17.4 million/year pre-pandemic 2017 to 2019 to $7.7 million in 2020) but partially rebounded to $13.7 million/year by 2023. High-value payments (>$10,000) increased significantly post-pandemic (mean 124/year, 2021-2023) compared to pre-pandemic (mean 75/year, 2017-2020, P < .0001). Food and beverage were the most frequent payment type (88%; 17% of total value), but the greatest payment value came from consulting fees (2.6% of payments; 36% of total value). The top 5 states for industry payments (IPs) were California, Texas, New York, Florida, and Pennsylvania, accounting for 45% of nationwide IPs. The Northeast had the highest per-physician payments, whereas the South received the highest percentage (35%) of total funds. Twenty-six companies accounted for 80% of payments. Conclusions: The number of IPs decreased significantly during the COVID-19 pandemic but has approached pre-pandemic levels, driven by increased high-value payments. A small number of companies account for most payments. There is significant geographical heterogeneity, suggesting regional differences in physician-industry engagement and potentially disparate patient access to innovations. Future studies should clarify how industry funding influences otolaryngology clinical practice.
19 January 2026 in Global Journal on Quality and Safety in Healthcare
Introduction: The OncotypeDX test for patients with breast cancer with early-stage, hormone-receptor–positive, HER2-negative disease can predict the benefit of adjuvant chemotherapy in addition to hormone therapy. Delivering OncotypeDX results in a timely manner is important to inform treatment decisions. We implemented a strategy to reduce the turnaround time (TAT) from breast surgery to OncotypeDX report at a large urban public safety-net hospital in New York City. Methods: The Plan-Do-Study-Act model was used to implement quality improvement changes. The goal was to improve efficiency to get treatment information for treatment decisions for patients with breast cancer and encourage teamwork with existing resources in the large public hospital. The primary measure was TAT from surgery to receiving OncotypeDX results in the electronic medical record (EMR). We compared TAT before and after the implementation of our strategy. The historical control included patients from May 2021 through March 2022, whereas the timeline after strategy implementation was from June 2023 to February 2024. The strategy involved the creation of a smartphrase in the EMR for breast surgery to identify and order OncotypeDX in eligible patients, and collaboration between breast surgery, pathology, vendor, and medical oncology. Results: The patient characteristics were similar both before and after implementing the strategy, including patient number (26 vs. 27) and mean age (61 vs. 59 years). Both groups were composed predominantly of ethnic minorities (64% vs. 59%). A higher percentage of patients were from medically underserved areas and populations (MUAs and MUPs) in the group after strategy implementation (35% vs. 44%, p = 0.65). Our strategy reduced the average TAT from 42 to 30 days. Conclusion: We developed a strategy to optimize the OncotypeDX workflow in a large safety net health system despite an increase in patients from MUAs and MUPs. Initiating ordering of OncotypeDX by breast surgery, along with communication with pathology, vendor, and medical oncology, significantly reduced TAT.